第一作者:
John S,Welch
第一单位:
the Department of Internal Medicine, Division of Oncology (J.S.W., L.D.W., G.L.U., A.G., M.H.T., I.P., R.R., T.A.F., K.E.S.-G., R.V., S.T.O., C.N.A., A.F.C., M.A.S., M.A.J., S.E.H., K.L., M.R.J., M.J.W., P.W., D.C.L., J.F.D., T.J.L.), and the Division of Biostatistics (J.D.B.), and the Department of Pathology and Immunology (E.J.D., B.T., Y.-S.L.), Washington University School of Medicine, and McDonnell Genome Institute, Washington University in St. Louis (A.A.P., C.A.M., C.C.F., M.O., R.S.F., R.K.W., L.D.W., T.J.L.) - both in St. Louis; the Departments of Internal Medicine (A.H., N.K., M.J.S., W.S.) and Pharmacy (R.W.K.), University of Chicago, Chicago; and the Department of Internal Medicine (T.A.G.), Massachusetts General Hospital, Boston.
作者:
主题词
5-甲基胞嘧啶(5-Methylcytosine);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗代谢药, 抗肿瘤(Antimetabolites, Antineoplastic);阿扎胞苷(Azacitidine);骨髓(Bone Marrow);女(雌)性(Female);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);骨髓增生异常综合征(Myelodysplastic Syndromes);前瞻性研究(Prospective Studies);危险因素(Risk Factors);存活率(Survival Rate);肿瘤抑制蛋白质p53(Tumor Suppressor Protein p53)
DOI
10.1056/NEJMoa1605949
PMID
27959731
发布时间
2022-03-31
- 浏览11

The New England journal of medicine
2023-2036页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文